Opportunistic infections in patients treated with immunotherapy for cancer.
about
Immune Checkpoint Blockade in Cancer TherapyManagement of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanomaImmune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control.Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab.Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients.Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat
P2860
Q26830509-C9A8DC79-294A-4C02-BBA2-C00B6C12E455Q31034415-B0F64EC0-9FDC-4591-8421-676DC13E61CEQ33607108-184F5930-0A10-417F-81AD-08BDCA6BAC6BQ34545316-33E67EFE-95E3-4E78-82A3-91381FF994A2Q34667977-DA8F4324-56CB-425E-9ED8-2A0454FFCB65Q36173638-8A223D6D-CEB0-410F-8DC6-84BCF081D67CQ36710927-84014B47-95AB-4BA9-8EEC-F57DF2495AB6Q37369239-37DC6A01-2DA0-4379-997A-16F758530F5DQ38577834-09222409-2FF4-4F95-98DC-084BF2789820Q38870763-6F0B35AE-A2A5-4E70-890C-C8D4871BB2A6Q38930084-3C911FB9-5A5D-4CFD-9BE6-EFB06E22D202Q40584154-B667461E-7DC2-41B1-A327-92D3F2A9EA6EQ40959994-4BE5CC5B-49F6-4855-80FE-BD0230F5B376Q42369857-472F8B35-90D4-4966-882C-89CAE2C97593Q47349715-38C2EAFC-227B-4DF3-A3CB-FBE61C30E608Q47928843-50363651-99A8-4D04-BF7C-1D7BD70335AAQ48155956-B9B557F6-92E6-4E75-B4CA-21BAAE64E343Q50086043-27281355-A598-4770-BFF3-67FD609004AC
P2860
Opportunistic infections in patients treated with immunotherapy for cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Opportunistic infections in patients treated with immunotherapy for cancer.
@en
type
label
Opportunistic infections in patients treated with immunotherapy for cancer.
@en
prefLabel
Opportunistic infections in patients treated with immunotherapy for cancer.
@en
P2093
P2860
P356
P1476
Opportunistic infections in patients treated with immunotherapy for cancer.
@en
P2093
Chrisann Kyi
Jedd D Wolchok
Matthew D Hellmann
Michael A Postow
Paul B Chapman
P2860
P2888
P356
10.1186/2051-1426-2-19
P577
2014-06-18T00:00:00Z